Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
Status
Conditions
Treatments
Details and patient eligibility
About
This study aims to evaluate the effect of vitamin D3 supplementation on disease activity and quality of life in IBD patients deficient in vitamin D, and also help determine the optimal dose of vitamin D3 for them.
Hypothesis: Supplementation of vitamin D3 in IBD patients with hypovitaminosis D can improve their quality of life and decrease IBD activity.
Full description
The incidence of hypovitaminosis D has been reported to be as high as 75% in patients with IBD. However, it is unclear whether low vitamin D levels contribute to the pathogenesis of IBD or are a consequence of IBD. Recent animal data studies suggest that maintenance of the epithelial barrier integrity in the large intestine by vitamin D is important in preventing IBD.
However, more evidence is required to determine the effect of vitamin D3 supplementation in patients with IBD. Furthermore, there is no clear consensus regarding the appropriate dose of vitamin D supplementation in IBD patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- 18 years of age or older
- 25(OH)D levels <30ng/ml
- willing to give informed written consent
Exclusion criteria
- Age < 18 years
- Women who are pregnant or planning to become pregnant
- Patients already taking vitamin D3 ≥2,000 IU/daily prior to study enrollment
Trial design
Primary purpose
Allocation
Interventional model
Masking
30 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal